secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2023-01-25T23:59:59+00:00
Accession:  0001213900-23-005155
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics prices $90M public offering of 60M shares at $1.50 per share
--------------------------------------------------------------------------------

- Offering of 60M shares of common stock at $1.50/share; gross proceeds ~$90M before expenses.
- Underwriters granted 30-day option to purchase up to 9M additional shares at same price.
- Closing expected on or about Jan 27, 2023; proceeds for general corporate purposes.
- Directors and executive officers subject to lock-up agreements until April 25, 2023.
- Credit Suisse and William Blair act as active book-running managers; Oppenheimer as passive.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023005155/0001213900-23-005155-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023005155/ea172170-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-005155

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer